THE US Food and Drug
Administration has approved
Probuphine, the first buprenorphine
implant for the maintenance
treatment of opioid dependence.
The product is designed to
provide a constant, low-level dose
of buprenorphine for six months
in patients who are already stable
on low-to-moderate doses of other
forms of buprenorphine, as part of
a complete treatment program.
The FDA said expanding the use
and availability of medication assisted
treatment options is
an important component of the
regulatory body’s opioid action plan
and one of three top priorities for
the U.S. Department of Health and
Human Services’ Opioid Initiative
aimed at reducing prescription
opioid and heroin related overdose,
death and dependence.The above article was sent to subscribers in Pharmacy Daily's issue from 30 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 May 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.